Tenderwize
Back to tender search

Open House Original Rebate Contracts 2025-05 - Emtricitabine/Tenofovir Disoproxil/Rilpivirine (Active Combination)

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 193 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-05 - Emtricitabin/Tenofovirdisoproxil/Rilpivirin (Wirkstoffkombination)

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

40 / 100

Complexity

30 / 100

Risk factors

Patent expiry or loss of market exclusivity automatically terminates the contract for the affected drug. This may resul...

No guaranteed sales volume or revenue; the rebate contract does not ensure actual prescriptions or market share.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Conclude rebate contracts for the drug combination Emtricitabine/Tenofovir Disoproxil/Rilpivirine
  • No individual negotiations; standard terms apply
Show full summary

This is an Open House procedure (not a public procurement) by Techniker Krankenkasse and other German health insurers to conclude rebate contracts under §130c SGB V for the drug combination Emtricitabine/Tenofovir Disoproxil/Rilpivirine. The procedure is open continuously until the contract end date (28 February 2027) and all eligible pharmaceutical entrepreneurs with a valid marketing authorization for the drug combination can join on non-negotiable standard terms. No estimated value is published and no exclusivity is granted.

Risks

Patent expiry or loss of market exclusivity automatically terminates the contract for the affected drug. This may resul...

No guaranteed sales volume or revenue; the rebate contract does not ensure actual prescriptions or market share.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur under §4(18) AMG for the offered drug
  • Must have a valid marketing authorization or be otherwise entitled to market the drug combination
  • Must have registered seat within Germany, EU, or EEA

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open House Original Rebate Contracts 2025-05 - Emtricitabine/Tenofovir Disoproxil/Rilpivirine (Active Combination)

The objective is to conclude rebate contracts with all eligible pharmaceutical entrepreneurs for the drug combination Emtricitabine/Tenofovir Disoproxil/Rilpivirine under uniform, non-negotiable conditions. The contract runs from 1 March 2025 to 28 February 2027 (max. 24 months), but ends automatically upon patent expiry or loss of market exclusivity.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Feb 2025 - Feb 2027

Category

Pharmaceutical products

Deadline

Deadline Feb 27, 2027

Procurement Details

Publication date
20 Jan 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
40386-2025

Documents (1)

Similar tenders